<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389086</url>
  </required_header>
  <id_info>
    <org_study_id>NL73593</org_study_id>
    <nct_id>NCT04389086</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy for Locally Recurrent Rectal Cancer</brief_title>
  <acronym>PelvEx II</acronym>
  <official_title>Multicentre, Open-label, Randomised, Controlled, Parallel Arms Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy Alone as Neoadjuvant Treatment for Locally Recurrent Rectal Cancer - PelvEx II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, open-label, parallel arms, phase IIII study that randomises patients
      with locally recurrent rectal cancer in a 1:1 ratio to receive either induction chemotherapy
      followed by neoadjuvant chemoradiotherapy and surgery (experimental arm) or neoadjuvant
      chemoradiotherapy and surgery alone (control arm)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a clear resection margin</measure>
    <time_frame>Scored within 1 one month of surgery</time_frame>
    <description>A resection margin is considered clear (R0), if there are no tumour cells in any of the resection surfaces as determined by microscopy (resection margin &gt; 0mm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local recurrence free survival</measure>
    <time_frame>Assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis free survival</measure>
    <time_frame>Assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic response</measure>
    <time_frame>Scored within 1 month of surgery</time_frame>
    <description>Scored according to Mandard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity induction chemotherapy</measure>
    <time_frame>Scored until one month after the last administration of the chemotherapy</time_frame>
    <description>Adverse events grade 3 or higher according to the NCI-CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance induction chemotherapy</measure>
    <time_frame>Scored within 1 month after start chemoradiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity chemoradiotherapy</measure>
    <time_frame>Scored until 3 months after the last administration of the radiotherapy</time_frame>
    <description>Adverse events grade 3 or higher according to the NCI-CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance chemoradiotherapy</measure>
    <time_frame>Evaluation at time of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients undergoing surgery</measure>
    <time_frame>Surgery is scheduled 10-14 weeks after finishing chemoradiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical characteristics</measure>
    <time_frame>Evaluation directly postoperative</time_frame>
    <description>including data on intra-operative radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major surgical morbidity</measure>
    <time_frame>30 and 90-days postoperative</time_frame>
    <description>Clavien-Dindo grade 3 or higher</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response</measure>
    <time_frame>Restaging is performed after 3 cycles of CAPOX (1 cycle is 3 weeks) or 4 cycles of CAPOX/FOLFOX (1 cycle is 2 weeks). Second restaging is performed 4-6 weeks after finishing chemoradiotherapy</time_frame>
    <description>mrTRG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer specific quality of life</measure>
    <time_frame>at baseline, 3 months and 12 months postoperative</time_frame>
    <description>QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>at baseline, 3 months and 12 months postoperative</time_frame>
    <description>EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colorectal cancer specific quality of life</measure>
    <time_frame>at baseline, 3 months and 12 months postoperative</time_frame>
    <description>QLQ-CR29</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">364</enrollment>
  <condition>Recurrent Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Induction chemotherapy + chemoradiotherapy + surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy + surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant chemoradiotherapy followed by surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination drug</intervention_name>
    <description>Induction chemotherapy consists of either three three-weekly cycles of CAPOX (oxaliplatin 130 mg/m2 BSA IV + capecitabine 1000 mg/m2 BSA, orally, twice daily) or four two-weekly cycles of FOLFOX (85 mg/m2 BSA of oxaliplatin IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV). It is left to the discretion of the treating medical oncologist which of the two will be administered. In case of (previous) unacceptable toxicity (physician's discretion) to oxaliplatin, FOLFIRI may be prescribed. FOLFIRI (180 mg/m2 BSA of irinotecan IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV) consists of four two-weekly cycles.
If a patient has stable or responsive disease, induction chemotherapy will be continued with either one three-weekly cycle of CAPOX or two two-weekly cycles of FOLFOX/FOLFIRI.</description>
    <arm_group_label>Induction chemotherapy + chemoradiotherapy + surgery</arm_group_label>
    <other_name>CAPOX</other_name>
    <other_name>FOLFOX</other_name>
    <other_name>FOLFIRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemoradiotherapy</intervention_name>
    <description>Concomitant chemotherapy agent: capecitabine
Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy.</description>
    <arm_group_label>Induction chemotherapy + chemoradiotherapy + surgery</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy + surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery locally recurrent rectal cancer</intervention_name>
    <description>Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon.
Intraoperative radiotherapy is optional.</description>
    <arm_group_label>Induction chemotherapy + chemoradiotherapy + surgery</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy + surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Confirmed locally recurrent rectal cancer after total or partial mesorectal resection
             for rectal cancer either by histopathology Ã³r clinically proven (evidence on imaging
             in combination with clinical findings, with consensus in MDT)

          -  Resectable disease determined by magnetic resonance imaging (MRI) or deemed resectable
             after neoadjuvant treatment with chemoradiotherapy.

          -  WHO performance score 0-1

          -  Written informed consent

        Exclusion Criteria:

          -  Radiological evidence of metastatic disease (e.g. liver, lung) at time of
             randomisation or in the six months prior to randomisation.

          -  Homozygous DPD deficiency

          -  Any chemotherapy in the past 6 months.

          -  Any contraindication for the planned chemotherapy (e.g. severe allergy, pregnancy,
             kidney dysfunction with creatinine clearance of &lt;30ml/min, thrombocytopenia of
             &lt;100x109/L), as determined by the medical oncologist.

          -  Radiotherapy in the past 6 months for primary rectal cancer.

          -  Any contraindication for the planned chemoradiotherapy (e.g. severe allergy to
             chemotherapy agent, no possibility for radiotherapy due to previous radiotherapy), as
             determined by the medical oncologist and/or radiation oncologist.

          -  Any contraindication for surgery, as determined by the surgeon and/or
             anaesthesiologist.

          -  Concurrent malignancies that interfere with the planned study treatment or the
             prognosis of resected LRRC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pim Burger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis Eindhoven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Voogt, MD</last_name>
    <phone>0031 40 2397152</phone>
    <email>eva.voogt@catharinaziekenhuis.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Miranda Kusters, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Arend Aalbers, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Eva Voogt, MD</last_name>
      <phone>0031 40 2397152</phone>
      <email>eva.voogt@catharinaziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Pim Burger, MD, PhD</last_name>
      <email>pim.burger@catharinaziekenhuis.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Klaas Havenga, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medical Centre</name>
      <address>
        <city>Leidschendam</city>
        <zip>2262 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreas Marinelli, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Centre</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Cornelis Verhoef, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catharina Ziekenhuis Eindhoven</investigator_affiliation>
    <investigator_full_name>J. W. A. Burger</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Locally recurrent rectal cancer</keyword>
  <keyword>Neoadjuvant therapy</keyword>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Resection margin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Participant-level datasets and statistical codes will become available upon reasonable request after the results of the study have been published.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>The full protocol and Dutch informed consent forms will be publicly accessible after approval of the medical ethics committee.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

